Lixte Biotechnology Faces Delisting Notice
Ticker: LIXT · Form: 8-K · Filed: Apr 18, 2025 · CIK: 1335105
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: LIXT
TL;DR
LIXT got a delisting warning, stock might be in trouble.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on April 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated in Delaware and its principal executive offices are located in Pasadena, California.
Why It Matters
This filing indicates potential issues with Lixte Biotechnology's compliance with stock exchange listing standards, which could impact its stock's tradability and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- April 17, 2025 (date) — Date of earliest event reported
- 001-39717 (other) — Commission File Number
- 20-2903526 (other) — IRS Employer Identification No.
FAQ
What specific listing rule or standard has Lixte Biotechnology Holdings, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that has not been met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 17, 2025.
In which state is Lixte Biotechnology Holdings, Inc. incorporated?
Lixte Biotechnology Holdings, Inc. is incorporated in Delaware.
What is the address of Lixte Biotechnology Holdings, Inc.'s principal executive offices?
The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
What is the company's telephone number?
The company's telephone number is (631) 830-7092.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 18, 2025 regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).